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Patient-Tailored Levothyroxine Dosage
with Pharmacokinetic/Pharmacodynamic Modeling:
A Novel Approach After Total Thyroidectomy
Vegard Heimly Brun,1,2,i Amund H. Eriksen,1 Ruth Selseth,1 Kenth Johansson,3
Renate Vik,4 Benedicte Davidsen,4 Michal Kaut,5 and Lars Hellemo5
Background: After seven decades of levothyroxine (LT4) replacement therapy, dosage adjustment still takes
several months. We have developed a decision aid tool (DAT) that models LT4 pharmacometrics and enables
patient-tailored dosage. The aim of this was to speed up dosage adjustments for patients after total thyroidectomy.
Methods: The DAT computer program was developed with a group of 46 patients post-thyroidectomy, and it was
then applied in a prospective randomized multicenter validation trial in 145 unselected patients admitted for total
thyroidectomy for goiter, differentiated thyroid cancer, or thyrotoxicosis. The LT4 dosage was adjusted after only
two weeks, with or without application of the DAT, which calculated individual free thyroxine (fT4) targets based
on four repeated measurements of fT4 and thyrotropin (TSH) levels. The individual TSH target was either <0.1,
0.1–0.5, or 0.5–2.0 mIU/L, depending on the diagnosis. Initial postoperative LT4 dosage was determined according
to clinical routine without using algorithms. A simplified DAT with a population-based fT4 target was used for
thyrotoxic patients who often went into surgery after prolonged TSH suppression. Subsequent LT4 adjustments
were carried out every six weeks until target TSH was achieved.
Results: When clinicians were guided by the DAT, 40% of patients with goiter and 59% of patients with cancer
satisfied the narrow TSH targets eight weeks after surgery, as compared with only 0% and 19% of the controls,
respectively. The TSH was within the normal range in 80% of DAT/goiter patients eight weeks after surgery as
compared with 19% of controls. The DAT shortened the average dosage adjustment period by 58 days in the
goiter group and 40 days in the cancer group. For thyrotoxic patients, application of the simplified DAT did not
improve the dosage adjustment.
Conclusions: Application of the DAT in combination with early postoperative TSH and fT4 monitoring offers a
fast approach to LT4 dosage after total thyroidectomy for patients with goiter or differentiated thyroid cancer.
Estimation of individual TSH-fT4 dynamics was crucial for the model to work, as removal of this feature in the
applied model for thyrotoxic patients also removed the benefit of the DAT.
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Introduction
An estimated 5% of the population require thyroxinereplacement therapy due to thyroid dysfunction or sur-
gery (1,2). In the United States, levothyroxine (LT4) has been
among the three most prescribed medications for years (3).
Surprisingly, dosage adjustment remains a significant clinical
problem even though LT4 has been on the market for almost
seven decades and was first synthesized in 1927 (4). The time
to achieve euthyroidism after thyroidectomy is often more
than a year (5,6). The long interval could be due to the long
half-life of LT4 (about one week), the narrow therapeutic
window, variations in bioavailability and pharmacodynam-
ics, and nonadherence. Long-term hypothyroidism and
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iatrogenic thyrotoxicosis have implications for cardiovascu-
lar disease, osteoporosis, quality of life, neurological disease,
dementia, cancer treatment, and even mortality (7–16). Shorter
periods with suboptimal dosage are more likely to affect qual-
ity of life, work capacity and have social consequences (17,18).
Several attempts have been made to predict the required
LT4 dosage after thyroidectomy or in treatment of hypothy-
roidism (5,6,19–23). The published dosage schemes are vari-
ations of weighted relationships between LT4 dosage
and person weight, height, sex, age, and drug interactions. At
best, they retrospectively predict the correct dosage for 60–
65% of the patients (1,23). However, prospective testing of the
formulas is limited and often provides inferior results. Leaving
a priori dosage estimates behind, we decided to use a patient-
tailored approach that estimates the free thyroxine (fT4)
pharmacokinetics and the thyrotropin (TSH)/fT4 relationship
for each individual patient based on repeated blood samples.
We hypothesized that rather than waiting six to eight weeks for
hormone levels to stabilize, dosage adjustments after only two
weeks would be feasible if the clinician was assisted by a
computerized decision aid tool (DAT) predicting the future
fT4 and TSH responses. We further assumed that the best
prediction could be done by combining population data and the
results of individual blood samples drawn during the first two
weeks after thyroidectomy. The objective of the study was to
test whether application of the DAT led to more efficient
dosage adjustments for patients starting LT4 therapy after total
thyroidectomy, as compared with randomized controls.
Methods
Participants
Patients >18 years old admitted for total thyroidectomy
or completion thyroidectomy after previous hemithyroidec-
tomy were recruited consecutively, after obtaining infor-
med consent. Their diagnosis was nontoxic goiter, thyroid
malignancy Graves’ disease, or toxic multinodular goiter.
Exclusion criteria were pregnancy, use of liothyronine, or
inability to cooperate on later follow-up by telephone. First,
46 patients were recruited for collection of pilot data that
were used to develop the DAT algorithms. Second, a vali-
dation group of 145 new patients (103 female) were con-
secutively recruited in a randomized controlled trial (RCT):
84 from the University Hospital of North Norway, 28 from
Haukeland University Hospital, Norway, and 33 from Väs-
tervik Hospital, Sweden. Ten patients were excluded after
enrolment in the RCT, because they did not take the blood
samples required by the study design (n = 7), because of tech-
nical problems with the DAT (server crash, n = 2), or because
of other health emergencies (n = 1). The excluded patients
were evenly distributed between the DAT and control groups
(Table 1). This left 135 participants for data analysis. Of
these, all completed the 8 weeks postoperative checkpoint
and 122 successfully completed dosage adjustment according
to the TSH goals in the study. The thyrotoxicosis/DAT group
consisted of 21 patients with Graves’ disease and 5 patients
with toxic nodular goiter, while the thyrotoxicosis/control
group contained 20 patients with Graves’ disease and 5 pati-
ents with toxic nodular goiter.
DAT development and validation study design
The DAT was developed on pilot data as described in
Supplemental Data. Briefly, the model parameters were de-
rived from four blood draws analyzed for TSH and fT4 ob-
tained during the first two weeks of LT4 therapy. We
assumed a log-linear relationship between TSH and fT4 (24),
and we modeled individual TSH-fT4 response and fT4 phar-
macokinetics informed by population data. Individual TSH-
fT4 responses are illustrated in Figure 1. We tested the DAT
in a prospective multicenter trial where participants were
randomized to either application of the DAT or not (controls).
We used an automated stratified randomization based on di-
agnosis and participating hospital. After surgery, and before
randomization, all participants were prescribed an LT4 start-
ing dosage, usually between 100 and 150 lg/day depending
on diagnosis, body weight, age, and comorbidity. They were
then asked to give pre-LT4 ingestion blood samples twice
per week for two weeks postoperatively (Fig. 2). To reduce
variation in the measurements and model, patients were
Table 1. Patient Characteristics for Validation Randomized Controlled Trial
Variable
Goiter Cancer Thyrotoxicosis
DAT Control DAT Control DAT Control All
No. total 16 18 29 28 28 26 145
No. exclusions 1 2 2 2 2 1 10
No. analyzed 15 16 27 26 26 25 135
Age (years) 55 – 4.6 55.9 – 4.1 57.5 – 2.3 55.7 – 2.6 51.5 – 2.8 53.8 – 2.9 54.8 – 1.2
Height (cm) 167 – 2 165 – 2 169 – 1 173 – 2 171 – 2 168 – 2 169 – 1
Weight (kg) 76.7 – 5.7 77.5 – 5 79.7 – 2.8 83.6 – 3.2 78.5 – 3.3 80.2 – 3.7 79.7 – 1.5
BMI (kg/cm2) 27.1 – 1.6 28.2 – 1.6 27.6 – 0.7 28 – 1.1 26.6 – 0.8 28.4 – 1.2 27.6 – 0.5
% Female 80 88 70 54 73 72 71
Initial LT4 dose (lg/day) 112 – 3 109 – 4 131 – 4 137 – 3 113 – 3 117 – 4 121 – 2
Final LT4 dose (lg/day) 117 – 9 118 – 12 144 – 7 150 – 7 119 – 5 114 – 7 129 – 3
TSH target <0.1 mIU/L 0 0 21 17 1 0 39
TSH target 0.1–0.5 mIU/L 0 0 5 8 4 4 21
TSH target 0.5–2.0 mIU/L 15 16 1 1 21 21 75
Baseline characteristics and dosage data for participants in the study. There was no statistical difference between the DAT groups and
control groups within each diagnosis group (all p-values <0.15). The lower three rows show the number of patients assigned to each
possible TSH target within each group.
BMI, body mass index; DAT, decision aid tool; LT4, levothyroxine; TSH, thyrotropin.
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instructed to take the medicine and give all blood samples in
the morning. On days of blood samples, patients were in-
structed to delay intake of LT4 until the blood was drawn.
Two to three weeks after surgery, the participants received a
follow-up call advising them to either keep the current dosage
or change it. In the DAT group, the responsible surgeon was
assisted by the DAT with a graphical plot of the predicted
fT4 and TSH given a suggested dosage change (Fig. 3). The
DAT was disabled in the control group, but the same blood
samples were available to the clinician. We collected pre-
operative data about diagnosis, TSH-target, height, weight,
age, sex, surgery date, creatinine, albumin, TSH, fT4, and free
triiodothyronine. Postoperative data were collected about
LT4 dosage, TSH, and fT4.
Eight weeks after surgery (i.e., 5–6 weeks after the first
follow-up), blood tests were again evaluated. If the TSH
target was reached, they left the study and continued follow-
ups by surgeons, endocrinologists, or general practitioners,
according to local routines. If the TSH target was not reached,
the participants entered loops of follow-up every six weeks
until the TSH target was reached (Fig. 2). On each follow-up,
the DAT was applied only to the DAT group.
Outcome measures
The primary endpoint in the study was the number of pa-
tients who reached their clinically determined TSH target
eight weeks after thyroidectomy. Before discharge, the sur-
geon assigned each patient to either substitution treatment
(TSH 0.5–2.0 mIU/L), mild suppression (TSH 0.1–0.5 mIU/L),
or full suppression (TSH <0.1 mIU/L and fT4 < 30 pmol/L),
depending on a clinical evaluation. Usually, patients with
goiter and thyrotoxicosis received substitution therapy, while
patients with cancer received suppression therapy (Table 1).
The secondary endpoint was the number of days from surgery
to the completion of LT4 dosage adjustment.
Ethical considerations and patient consent
The study was approved by the Norwegian Regional Ethics
Committee (2016/1782) and by the Swedish Ethical Review
Authority (443-17). All participants, including the ones con-
tributing to pilot data, signed a written consent form. Very
few (<5%) declined the invitation to participate. Patients re-
ported no perceived ethical dilemma participating in the
study and did not receive any financial compensation.
FIG. 1. Measurements of TSH and fT4 from a subset of the RCT population (left) and two example patients (center and
right) during the first two weeks after thyroidectomy. Hyper parameters of the Bayesian regression lines estimated from the
pilot population used to develop our model. For estimation of individual TSH/fT4 relationships a Bayesian regression model
was used instead of OLS to compensate for the low number of samples and for censoring. Center: A patient without
detectable TSH, naive OLS would give flat/no response. The Bayesian model gives more plausible estimate with response
extending below censoring limit, slope is informed by population data. Right: Bayesian slope is less steep than naive patient
specific OLS as informed by population data. fT4, free thyroxine; OLS, ordinary least squares; RCT, randomized controlled
trial; TSH, thyrotropin.
FIG. 2. Study design for randomized controlled validation trial. After total thyroidectomy, the surgeon chose an LT4
starting dosage based on diagnose and clinical routine. TSH and fT4 was measured four times the next two weeks to allow
early dosage adjustment. The patients were randomized to the application of a DAT or not (control) for dosage adjustments
that were supervised by an experienced endocrine surgeon in either case. Eight weeks after surgery, successful dosage
adjustment was evaluated based on TSH measurements. If the TSH target was not achieved, the patient continued six-week
dosage adjustment cycles. DAT, decision aid tool.
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Statistical methods and data analysis
All values are reported mean – standard error of the mean.
We used two-tailed Student’s t-tests, univariate analysis of
variance, and Pearson Chi-square tests for all statistics. The
Markov Chain Monte Carlo model (25) is written in JAGS
(26), with pre- and postprocessing in Julia (https://julialang
.org). Data were collected by using Microsoft Access for the
pilot study, and using REDCap for the multicenter study.
Final results were exported for statistical analysis in Micro-
soft Excel, SPSS, and Julia. The dosage optimization was
calculated by using JuMP (27) and Couenne (https://github
.com/coin-or/Couenne).
Results
The DAT was tested in a validation RCT on patients di-
agnosed with goiter and differentiated thyroid cancer, and the
simplified DAT was tested on patients with thyrotoxicosis.
There was no statistical difference between the DAT and
control groups in the basic characteristics of the groups, nor
in the initial and final dosages of LT4 (Table 1, multiple
t-tests, uncorrected p-values >0.15 for all variables). Most
patients with cancer received TSH suppression, while all
patients with goiter and most patients with thyrotoxicosis
received replacement therapy. There was no difference in
clinically decided TSH targets between DAT and controls (all
patients with goiter had the same TSH target, Pearson Chi-
square p = 0.58 for cancer and p = 0.61 for thyrotoxicosis).
Faster dosage adjustment with DAT in patients
with goiter and cancer
For all RCT-groups together, 24 of 68 patients (35%) had
reached their narrow TSH targets eight weeks after surgery if
the dosage adjustment was assisted by the DAT, in contrast to
10 of 67 patients (15%) in the control group (Chi-square =
7.43, p = 0.006). As the applied DAT for thyrotoxic patients
used a simplified population based fT4 target, in contrast to
the individually estimated fT4 targets for patients with goiter
and cancer, all further analysis was done on subgroups. Forty
percent of patients with goiter and 59% of patients with
cancer in DAT groups were within the TSH target after
8 weeks compared with 0% and 19% in control groups, re-
spectively (Fig. 4A, Chi-squares 7.94, p = 0.005 and 8.87,
p = 0.003). To make our results more comparable with other
published dosage schemes, we also calculated the proportion
of patients with goiter with TSH within the normal refer-
ence range rather than within the narrower TSH goal (0.5–
2.0 mIU/L) used in the study. The reference range was 0.2–
4.3, 0.3–3.7 or 0.4–4.5 mIU/L depending on the recruiting
hospital. After 8 weeks, 80% of patients with DAT had TSH
values within the normal range, which was significantly
higher than 19% of controls (Chi-square 9.31, p = 0.002).
To evaluate how the DAT impacted the clinician’s deci-
sion after two to three weeks, we classified the early adjust-
ments as either in the ‘‘right direction’’ (toward what later
became the final dosage) or in the opposite ‘‘wrong direc-
tion,’’ or as ‘‘no change’’ (Table 2). For all control groups,
‘‘no change’’ was the preferred choice, while adjustments in
the right direction was far more common than wrong direc-
tion adjustments for all groups. For statistical analysis, the
difference between LT4 dosage at any timepoint and the final
dosage was calculated for the first 20 weeks (Fig. 4B). After
2 weeks, clinicians made significant adjustments toward the
‘‘correct’’ final dosage for patients with DAT [t(65) = 3.31,
p = 0.002], but not for controls [t(65) = 1.00, p = 0.32]. Sub-
group analysis revealed that the effect of DAT was present in
both goiter [t(15) = 3.16, p = 0.006] and cancer [t(27) = 3.52,
p = 0.002] groups. The results from control groups indicate
that the experienced clinicians were not able to make sig-
nificant dose adjustments based on the TSH and fT4 values
from the first two weeks without assistance of the DAT. The
effect of the DAT in goiter and cancer groups was reflected in
the total time to reach TSH targets (Fig. 4C). The average
time to reach the TSH targets in the DAT/goiter group was
105 – 13 days compared with 162 – 17 days in the control/
goiter group [t = t(25) = 2.59, p = 0.016]. The DAT/cancer
group reached TSH targets on average 87 – 10 days after
surgery, significantly shorter than 127 – 13 days in controls
[t(49) = 2,48, p = 0.017].
No effect of population-based DAT version
for thyrotoxic patients
In the thyrotoxicosis group, we could not reliably esti-
mate individual fT4 targets due to frequent TSH suppres-
sion. Instead, we applied a simplified DAT version with a
population-based fT4 target. The number of patients who
reached their TSH target after 8 weeks was not different
between the DAT and control groups (Fig. 5A; Chi-square
1.63, p = 0.20).
A
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FIG. 3. Output from the DAT guided the clinician to in-
crease LT4 dosage 20 days after thyroidectomy, when the
DAT was applied in this example patient (same as in Fig. 1,
right). A near twofold increase in dosage is suggested to
reach the target of TSH <0.10 mIU/L. The plots show the
actual measurements of fT4 (A) and TSH (B) alongside the
model estimates. The suggested dosages and the projected
responses are also shown to facilitate evaluation from the
clinician before deciding on the final dosage.




FIG. 4. Number of patients (above bars)
who achieved their TSH goals eight weeks
after thyroidectomy and initiation of LT4
replacement therapy. (A) When the DAT was
applied, more patients reached their narrow
TSH goal after 8 weeks in patients treated for
goiter ( p = 0.005) and cancer ( p = 0.003). For
goiter patients, light color illustrates the
proportion of patients with TSH within the
normal reference range as compared with
the narrower TSH target in the study (0.5–
2.0 mIU/L, dark colors). (B) Dynamics of
LT4 dosage adjustments and total distance to
reach TSH goals. Distance to final LT4 dos-
age during the first 20 weeks of follow-up for
patients with goiter and cancer. Light colors
indicate CIs. The distance to the final dosage
dropped significantly after 2 weeks in DAT
groups [goiter t(15) = 3.16, p = 0.003, cancer
t(27) = 3.52, p = 0.001], but not in controls
(n.s.). (C) Violin plots showing time to
achieve TSH targets (black dots for individ-
ual patients). Median is indicated in white
lines, and quartiles are indicated in black
dotted lines. The TSH targets were reached
earlier in the goiter ( p = 0.016) and cancer
( p = 0.017) groups that used the DAT. CI,
confidence interval.
Table 2. Classification of Early Dosage Adjustments
Variable
Goiter Cancer Thyrotoxicosis
DAT Control DAT Control DAT Control
No adjustment 3 7 5 13 6 16
Right direction 11 6 20 8 12 8
Wrong direction 1 2 2 4 5 1
The dosage adjustments that were performed after two to three weeks, based on early blood samples after thyroidectomy, showed that less
adjustments were made in control groups compared with DAT groups. Most adjustments were made in the direction of the final dosage for
each patient, termed ‘‘right direction,’’ while a few were made in the opposite ‘‘wrong direction.’’
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The DAT group spent longer than controls to finalize dos-
age adjustment [182 – 20 days vs. 115 – 12 days, t(42) = -2.96,
p = 0.005], indicating that clinicians were misinformed by the
DAT for this group (Fig. 5B). Undetectable TSH levels was a
significant problem in this group, as 16 out of 26 patients
had TSH below the laboratory’s detection level (0.01–0.05
mIU/L depending on hospital) preoperatively, of whom 10
remained with undetectable TSH values during blood sam-
ples the first 2 weeks. Excluding these 10 DAT patients from
analysis eliminated the group difference regarding time to
finalize dosage adjustment [t(34) = 1.76, p = 0.09].
To check whether the surgeons responsible for dosage
adjustment followed the suggestions of the DAT, we calcu-
lated the difference between DAT suggestion and the actual
prescribed dosage at the two-week follow-up. The deviation
was 16.4 – 4.6 lg/day in the thyrotoxicosis group, in contrast
to 4.9 – 2.3 lg/day in the goiter group and 7.7 – 2.4 lg/day
in the cancer group. There was a significant effect of group
[one-way analysis of variance F(2,64) = 4.19, p = 0.019], and
subsequent orthogonal testing revealed that the surgeons de-
viated significantly more from the suggested dosage in the
thyrotoxicosis group compared with the two other groups
[t(64) = 2.47, p = 0.016]. There was no significant difference
between the goiter and cancer groups [t(64) = 1.18, p = 0.24].
Cost versus benefit
The average follow-up period in the study was 127 – 6.4
days, or *18 weeks, ranging from 47 to 468 days. The average
number of postoperative blood draws in this period was
6.6 – 0.15, and the average number of follow-up visits was
3.6 – 0.14 (Table 3). For goiter and cancer groups, the appli-
cation of the DAT reduced the number of blood draws needed
[t(25) = 2.47, p = 0.02 and t(50) = 3.14, p = 0.003 respectively]
and the number of follow-up visits [t(25) = 2.16, p = 0.04 and
t(50) = 3.15, p = 0.003] as compared with their respective con-
trols. As our RCT did not have a control arm with an ordinary
standard of care, we made a comparison with retrospective data
from a similar population operated three years before the DAT
study (Supplementary Table S1). Lab records from these pa-
tients showed that the average number of blood draws before
the TSH targets were reached was 8.6, which is higher than for
patients in the current RCT (Supplemental Data).
FIG. 5. Number of thyrotoxic patients (above bars) who
achieved their TSH goals eight weeks after thyroidectomy
and initiation of LT4 replacement therapy. (A) Application
of a simplified DAT, which only used population-based fT4
targets, had no effect on the number of patients who reached
their TSH target after eight weeks ( p = 0.20). (B) Distance
to final LT4 dosage during the first 20 weeks of follow-up
for patients with thyrotoxicosis. Light colors indicate CI.
Distance to final dosage was not significantly reduced in the
DAT group after 2 weeks [t(21) = 0.99, p = 0.34]. (C) Violin
plots for time to achieve TSH targets with black dots for
individual patients. Median is indicated in white lines, and
quartiles are indicated in black dotted lines. It took longer to
reach the TSH targets when the simplified DAT was used, as
compared with controls [t(42) = -2,96, p = 0.005].
Table 3. Biochemical Data
Variable
Goiter Cancer Thyrotoxicosis
DAT Control DAT Control DAT Control All
TSH preoperative (mIU/L) 1.23 – 0.2 1.13 – 0.2 2.88 – 0.5 2.74 – 0.42 0.78 – 0.31 1.37 – 0.57 1.77 – 0.19
TSH 8 weeks (mIU/L) 2.03 – 0.50 4.88 – 2.35 0.42 – 0.24 0.50 – 0.15 5.75 – 1.83 1.49 – 0.44 2.36 – 0.49
TSH final (mIU/L) 1.16 – 0.18 1.15 – 0.13 0.15 – 0.06 0.14 – 0.03 1.17 – 0.23 0.95 – 0.11 0.71 – 0.07
fT4 preoperative (pmol/L) 16.3 – 0.6 15.1 – 0.5 15.8 – 0.6 16.8 – 0.7 22.1 – 3.4 17.8 – 1.4 17.6 – 0.8
fT4 8 weeks (pmol/L) 19.0 – 1.0 20.2 – 1.1 24.6 – 1.0 24.3 – 1.3 19.3 – 1.2 19.1 – 0.7 21.3 – 0.5
fT4 final (pmol/L) 19.3 – 1.0 18.0 – 0.9 24.3 – 0.8 22.6 – 0.7 20.1 – 0.9 18.3 – 0.4 20.8 – 0.4
No. of postoperative blood draws 5.8 – 0.38 7.1 – 0.40 5.8 – 0.17 6.9 – 0.30 7.8 – 0.52 6.2 – 0.27 6.6 – 0.15
No. of postoperative visits 3.1 – 0.31 4.1 – 0.34 2.8 – 0.17 3.8 – 0.30 4.67 – 0.48 3.3 – 0.25 3.6 – 0.14
Biochemical data preoperatively, after eight weeks and at the end of the study period (final), and the total number of blood draws and
follow-up visits for the validation RCT (average – SEM). The TSH reference range for TSH was 0.2–4.3, 0.3–3.7, and 0.4–4.5 mIU/L in the
three recruiting hospitals. fT4 reference range was 9–22, 12–22, and 9.5–22 pmol/L.
fT4, free thyroxine; LT4, levothyroxine; SEM, standard error of the mean.
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Discussion
This is the first study to suggest LT4 dosage adjustment
based on repeated fT4 and TSH measurements during the first
two weeks after thyroidectomy. Application of the DAT en-
abled the clinician to make appropriate dosage adjustments
after only two weeks. It is hard to compare the performance of
our model directly against other published dosage schemes,
because they all use the entire TSH reference range as goal
achievement (5,6), while we used a narrower TSH target also
for replacement therapy. The reason we did not include TSH
range >2.0 mIU/L in our targets was that high normal TSH
values are associated with comorbidity (12,28–31), and to
make our TSH targets more applicable to all diagnoses in the
study, including cancer. The study was thus not designed to
evaluate our model against other published dosage schemes,
but to evaluate whether computerized modeling would allow
meaningful early LT4 dose adjustments, before a steady state
is reached. When recalculating our eight-week data for pati-
ents with goiter using the entire TSH reference range as goal
achievement, we found, however, that our model outperforms
other published dosage schemes. Care must be taken when
interpreting these data, as the number of patients is low both in
our study groups and in comparable studies.
The consequences of efficient dosage adjustments after
thyroidectomy in terms of work capacity, sick leave, quality
of life, or other patient-reported outcomes have to be deter-
mined before we know whether a minimum of five postop-
erative blood draws is acceptable. The number is comparable
with routine follow-up in the first author’s clinic before de-
velopment of the DAT (Supplemental Data). There is, how-
ever large variation in the reported number of necessary
dosage adjustments after thyroidectomy (32–34), probably
reflecting that optimal care is yet to be established. We be-
lieve that the advantages of the DAT outweigh the extra cost
of early blood samples, for example by reducing the number
of follow-up visits and shortening the dosage adjustment
period. In addition, further refinement of our model could
lower the number of needed samples.
The failure of the simplified DAT to improve dosage for
thyrotoxic patients suggests that individual fT4-TSH estima-
tions are necessary to achieve successful dosage with our
model. The majority of the patients in the thyrotoxicosis group
had a totally suppressed TSH before surgery and were still
on anti-thyroid hormone drugs. Slow recovery of normal TSH
dynamics after prolonged suppression made our model vul-
nerable to mistakes, as it relied heavily on initial blood sam-
ples. In addition, our assumption that a log-linear relationship
exists between TSH and fT4 (32–34) may not be valid for this
group. The overall altered metabolism in patients with Graves’
disease could also be changing during the course of follow-up,
making initial estimations invalid later on.
In conclusion, application of the DAT for LT4 dosage was
superior to clinician dosage adjustment in patients who were
euthyroid before total thyroidectomy. Further studies should
include patient-reported outcome measures and investigate
whether faster dosage adjustment has direct implications for
health or quality of life.
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